Pasithea Therapeutics Corp. (KTTA) Financials

KTTA Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 56.4 million 1.5 million
Dec. 31, 2025 60.2 million 5.0 million
Sept. 30, 2025 13.6 million 1.4 million
June 30, 2025 17.0 million 1.8 million

KTTA Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -4.8 million 139.2 million
Dec. 31, 2025 -5.4 million -67.8 million
Sept. 30, 2025 -2.9 million 209.0 million
June 30, 2025 -3.9 million 57645

KTTA Net Income

No data available :(

KTTA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 50.4 million - -
Dec. 31, 2025 55.2 million - -
Sept. 30, 2025 4.1 million - -
June 30, 2025 7.2 million - -

KTTA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 7.0 million
Dec. 31, 2025 7.0 million
Sept. 30, 2025 7.4 million
June 30, 2025 5.6 million

KTTA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 2.9 billion 1.9 billion -
Dec. 31, 2025 - 2.7 million 7.5 million -
Sept. 30, 2025 5 1.4 million 1.8 million -
June 30, 2025 4 2.1 million 1.7 million -

KTTA Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 157541
Dec. 31, 2025 - 157962
Sept. 30, 2025 - 181541
June 30, 2025 - 161745

KTTA

Price: $0.50

52 week price:
0.28
2.06

Earnings Per Share: -1.42 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 51500

Market Capitalization: 19.5 million

Links: